To determine, if ERK1/2 activation occurs in patient tumour samples and could potentially reduce the anti-tumour effect of cetuximab, we surveyed TMAs with newly diagnosed chemo-naive HNSCC, where the primary treatment included concurrent standard radiotherapy with single-agent cetuximab application. The gene discussed is MAPK3; the disease is head and neck squamous cell carcinoma.